This study provides clear evidence that a vaccine specifically designed to deliver peptides to lymphatic organs can consistently induce both CD4+ and CD8+ T cell responses that drive tumor regression, particularly when combined with checkpoint inhibition. Here, CD8A is linked to neoplasm.